Clinical Research Directory

Inclusion Criteria: 1. Age: 18-80 years old; 2. Pathologically confirmed pancreatic cancer and underwent pancreaticoduodenectomy(involved removing 50% of the pancreas, leaving 50% of the pancreas, ensuring balanced grouping); 3. Presence of EPI symptoms (such as steatorrhea) and/or constipation (Bristol type 1-2, with \<3 bowel movements per week); 4. Have informed consent and be proficient in using smartphone apps; 5. Patients who are intended to receive treatment with either Daitong Capsules or Shouhui Tongbian Capsules, or both; 6. The patient's condition is stable and suitable for participation in this study, as confirmed by investigator; 7. Willing and able to follow the medication and follow-up plan specified in the study protocol, with an expected medication adherence rate of over 80%. Exclusion Criteria: 1. Allergic to pancreatic enzyme (porcine-derived protein allergy) or any ingredient of Shouhui Tongbian Capsules; 2. Have a history of liver damage caused by Polygonum multiflorum; 3. Combined with intestinal obstruction, severe hepatic and renal insufficiency (Child-Pugh Class C, eGFR \< 30 ml/min), etc; 4. Pregnant or lactating women; 5. Psychological cognitive impairment. 6. It is expected that the 12-weeks follow-up will not be completed.